Results 121 to 130 of about 98,417 (285)

Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States

Frontiers in Immunology
ObjectiveNivolumab, recently proven in a phase 3 clinical trial (CheckMate 901) to enhance survival when combined with gemcitabine-cisplatin for advanced urothelial carcinoma.
Guiyuan Xiang, Yueyue Huang, Yueyue Huang, Lanlan Gan, Linning Wang, Yunqi Ding, Yuanlin Wu, Haiyan Xing, Yao Liu   +8 more
doaj   +1 more source

Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials

, 2018
Jiamin Jin, Chunbo Teng, Tao Li College of Life Science, Northeast Forestry University, Harbin, China Purpose: We aimed to compare the efficacy of combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer (PC) by ...
Jin JM, Li T, Teng CB
core  

The current and future burden and cost of overactive bladder in five European countries.

, 2006
OBJECTIVE: To estimate and compare the current and future direct cost of overactive bladder (OAB) to the health care systems of five European countries.
Reeves, Penny, Kelleher, Con, Kopp, Zoe, Lloyd, Adam, Irwin, Deb, Milsom, Ian, Calvert, Neill   +6 more
core   +1 more source

Autophagy Plays a Suppressive Role in Bladder Tumor Formation in an Orthotopic Mouse Model and Bladder Cancer Patient Specimens

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Autophagy plays either a suppressing or promoting role during tumor development. Clarifying the role of autophagy in bladder tumorigenesis both in vitro and in vivo is crucial for developing novel therapeutic strategies through manipulating autophagy activity.
Wan‐Ting Kuo, Chin‐Chen Pan, Yi‐Wen Liu, Nan‐Haw Chow, Hong‐Lin Cheng, Shan‐Ying Wu, Sheng‐Hui Lan, Chih‐Peng Chang, Hsiao‐Sheng Liu   +8 more
wiley   +1 more source

Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC

, 2007
Gemcitabine (2'2'-difluorodeoxycytidine) is a pyrimidine analog used in the treatment of a variety of solid tumors. After intravenous (i.v.) administration, it is rapidly inactivated to 2'-deoxy-2',2'-difluorouridine (dFdU). A sensitive analytical method
Lanz, Christian, Früh, Martin, Thormann, Wolfgang, Lauterburg, Bernhard H, Cerny, Thomas   +4 more
core   +1 more source

Oncogenic KRAS Rewires Stress Granule Dynamics: Mechanisms and Therapeutic Opportunities

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Stress granules (SGs) are dynamic, membrane‐less structures that form in response to various cellular stresses, including metabolic, oxidative, and therapeutic challenges. They function as adaptive hubs and reorganize protein synthesis and signaling networks to help cells survive under stress. In cancer, these condensates are often hijacked to
Msimisi Ndzinisa, Birhanetensay Masresha Altaye, Yuh‐Pyng Sher   +2 more
wiley   +1 more source

Aliphatic Poly(Carbonate)s with Acid Responsive Release Mechanisms for Micellar Anti‐Tumor Drug Delivery

Macromolecular Rapid Communications, EarlyView.
Micellar systems based on biodegradable aliphatic polycarbonates and acid‐responsive triggers enhance drug solubility, stability, and tumor‐selective release. This review covers micelles with acid‐cleavable drug linkages and those that disassemble via acid‐sensitive functionalities.
Adrian V. Hauck, Lutz Nuhn
wiley   +1 more source

Setting the record straight: Activity of gemcitabine monotherapy for breast cancer - Reply [PDF]

, 2004
Heinemann, Volker
core   +1 more source

Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives

, 2012
Cinzia Federico, Valeria M Morittu, Domenico Britti, Elena Trapasso, Donato CoscoDepartment of Health Sciences, Building of BioSciences, University “Magna Græcia” of Catanzaro, Campus Universitario “S Venuta& ...
Federico C, Cosco D, Morittu VM, Britti D, Trapasso E   +4 more
core  

Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study

Nutrition in Clinical Practice, EarlyView.
Abstract Background Pancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
Pamela N. Klassen, Christina A. Kim, Jessica Kasnik, Michael B. Sawyer, Sunita Ghosh, Vickie Baracos, Vera C. Mazurak   +6 more
wiley   +1 more source